Bravo Pharmaceuticals Private Limited, a active private limited company, was established on 14 June 2011 in New Delhi, Delhi, India. Engaging in pharmaceutical retailers & distributors within the trade sector, it holds CIN: U33110DL2011PTC220862. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹12.00 Cr and a paid-up capital of ₹1.00 Cr.
It upholds a compliant status. Its leadership includes Shreekant Panday (Director), Rakesh Pandey (Director), Reena Singh (Director). Past directors included Abha Kumar, Sumit Kalia, Praveen Sachdeva. It holds ₹18.68 Cr open charges and no settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at C-2, 3Rd Floor, Commercial Complex, Safdarjung Development Area, New Delhi, Delhi, 110016.
U33110DL2011PTC220862
220862
14 June 2011
₹12.00 Cr
₹1.00 Cr
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Bravo Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shreekant Panday | Director | 02 Sep 2022 | Current |
| Rakesh Pandey | Director | 14 Jun 2011 | Current |
| Reena Singh | Director | 24 Jun 2012 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 01 Mar 2021 | Past |
| Pramod Abcsdd | Additional Director | 27 Sep 2013 | Past |
| Pramod Abcsdd | Director | 27 Sep 2013 | Past |
| Pramod Abcsdd | Additional Director | 29 Sep 2024 | Past |
| Pramod Abcsdd | Director | 19 Oct 2020 | Past |
| Pramod Abcsdd | Director | 27 Sep 2013 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Bravo Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 89.23% decrease. The company also saw a substantial fall in profitability, with a 3507.63% decrease in profit. The company's net worth dipped by a decrease of 1.75%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Bravo Pharmaceuticals had a public holding of 24.66%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹186,836,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Dec 2024 | Axis Bank Limited | ₹3.14 M | Open |
| 14 Feb 2024 | Others | ₹2.00 Cr | Open |
| 23 Aug 2023 | Others | ₹1.88 Cr | Open |
| 23 Aug 2023 | Others | ₹14.49 Cr | Open |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Bravo Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Bravo Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bravo Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on A charge with Axis Bank Limited amounted to Rs. 0.31 Cr with Charge ID 101017505 was registered on 12 Dec 2024. was documented.
Progress on Bravo Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was documented.
Bravo Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi. was recorded as a recent event.
The activity A charge with Others amounted to Rs. 2.00 Cr with Charge ID 100882278 was registered on 14 Feb 2024. was completed.
The activity A charge with Others amounted to Rs. 1.88 Cr with Charge ID 100779776 was registered on 23 Aug 2023. was completed.
Progress on A charge with Others amounted to Rs. 14.49 Cr with Charge ID 100779772 was registered on 23 Aug 2023. was documented.
The CIN of Bravo Pharmaceuticals Private Limited is U33110DL2011PTC220862.
Bravo Pharmaceuticals Private Limited is headquartered at C-2, 3Rd Floor, Commercial Complex, Safdarjung Development Area, New Delhi, Delhi, 110016.
Bravo Pharmaceuticals Private Limited was incorporated on 14 June 2011.
The current directors of Bravo Pharmaceuticals Private Limited are
The primary industry of Bravo Pharmaceuticals Private Limited is Trade.
Bravo Pharmaceuticals Private Limited is unlisted.
The authorized capital of Bravo Pharmaceuticals Private Limited is ₹12.00 Cr, and the paid-up capital is ₹1.00 Cr.
The compliance status of Bravo Pharmaceuticals Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX